ArticleBiomolecules2021
Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- A Preliminary Evaluation ofPharmaceutics · 2026Article
- Assessment of potential nephrotoxicity biomarkers after [Scientific reports · 2026Article
- Could we reduce renal toxicity of [European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluation of coadministration schedules of rA1M for kidney protection after administration of 177Lu-octreotide.Radiation protection dosimetry · 2025Article
- Early apoptotic response in kidney after 177Lu-octreotate administration with or without potential radioprotector α1-microglobulin.Radiation protection dosimetry · 2025Article
- JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Single Chelator-Minibody Theranostic Agents forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Hematological and renal toxicity in mice after three cycles of high activity [Scientific reports · 2024Article
- Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [Theranostics · 2024Article
- Humanized Mice as a Model to Assess the Response of Human Hematopoietic Stem Cells to Irradiation.Bulletin of experimental biology and medicine · 2023Article
- No Evidence for Myocarditis or Other Organ Affection by Induction of an Immune Response against Critical SARS-CoV-2 Protein Epitopes in a Mouse Model Susceptible for Autoimmunity.International journal of molecular sciences · 2023Article
- Recombinant αBiomolecules · 2023Article
- Co-administration with A1M does not influence apoptotic response ofScientific reports · 2023Article
- Hematological Toxicity in Mice after High Activity Injections ofPharmaceutics · 2022Article
- Kidney Protection with the Radical Scavenger αAntioxidants (Basel, Switzerland) · 2021Review
- Evaluation of the PSMA-Binding LigandInternational journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Anti-prostate specific membrane antigen (PSMA) radioligand therapy is promising but not curative in castration resistant prostate cancer. One way to broaden the therapeutic index could be to administer higher doses in combination with radioprotectors, since administered radioactivity is kept low today in order to avoid side-effects from a high absorbed dose to healthy tissue. Here, we investigated the human radical scavenger α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.